Maintaining stability of sinus rhythm in atrial fibrillation: Antiarrhythmic drugs versus ablation

被引：2

作者：

Naccarelli G.V. ^{[1
]}

Hynes J. ^{[1
]}

Wolbrette D.L. ^{[1
]}

Bhatta L. ^{[1
]}

Khan M. ^{[1
]}

Luck J. ^{[1
]}

机构：

[1] Division of Cardiology, Hershey Medical Center, Hershey, PA 17033

来源：

Current Cardiology Reports | 2002年 / 4卷 / 5期

关键词：

Atrial Fibrillation; Amiodarone; Sinus Rhythm; Quinidine; Catheter Ablation;

D O I：

10.1007/s11886-002-0042-4

中图分类号：

学科分类号：

摘要：

In managing atrial fibrillation, the main therapeutic strategies include rate control, termination of the arrhythmia, and pr vention of recurrences and thromboembolic events. Rate control with digoxin, ß-blockers, verapamil, and diltiazem may be preferred in drug refractory and sedentary patients with markedly dilated left atrium and atrial fibrillation of long duration. Drugs useful in the maintenance of sinus rhythm include quinidine, procainamide, disopyramide, sotalol, amiodarone, dofetilide, flecainide, and propafenone. In patients with structural heart disease, the class III antiarrhythmics are the initial drugs of choice, given their neutral effects on survival in a post-myocardial infarction and congestive heart failure population. Due to high recurrence rates with pharmacologic therapy, nonpharmacologic options of therapy include atrioventricular junction ablation, atrial defibrillators, catheter ablation of pulmonary vein foci, and attempts to perform an atrial Maze procedure using catheters. Hybrid therapy using drugs in combination with nonpharmacologic approaches will be used more frequently in the future for refractory patients. Copyright © 2002 by Current Science Inc.

引用

页码：418 / 425

页数：7

共 88 条

[1]

Kannel W.B., Abbot R.D., Savage D.D., McNamara P.M., Epidemiologic features of chronic atrial fibrillation, N Eng J Med, 306, pp. 1018-1022, (1982)

[2]

Wolf P.A., Abbott R.D., Kannel W.B., Atrial fibrillation as an independent risk factor for stroke: The framingham study, Stroke, 22, pp. 983-988, (1991)

[3]

Alpert J.S., Petersen P., Godtfredsen J., Atrial fibrillation: Natural history, complications and management, Ann Rev Med, 39, pp. 41-52, (1988)

[4]

Benjamin E.J., Levy D., Vaziri S.M., Et al., Independent risk factors for atrial fibrillation in a population-based cohort: The framingham study, JAMA, 271, pp. 840-844, (1994)

[5]

Brand F.N., Abbott R.D., Kannel W.B., Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up on the framingham study, JAMA, 254, pp. 3449-3453, (1985)

[6]

Kopecky S.L., Jersh B.J., McGoon M.D., Et al., The natural history of lone atrial fibrillation. A population based study over three decades, N Eng J Med, 317, pp. 669-674, (1987)

[7]

Zipes D.P., Atrial fibrillation: From cell to bedside, J Cardiovasc Electrophysiol, 8, pp. 927-938, (1997)

[8]

Haissaguerre M., Jais P., Shah D.C., Et al., Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins, N Engl J Med, 339, pp. 659-666, (1998)

[9]

Wijffels M.C.E.F., Kirchhof C.J.H.J., Dorland R., Allessie M.A., Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats, Circulation, 92, pp. 1954-1968, (1995)

[10]

Tieleman R.G., Delangen C.D.H., Can G.I.C., Et al., Verapamil reduces tachycardia-induced electrical remodeling of the atria, Circulation, 95, pp. 1945-1953, (1997)

← 1 2 3 4 5 6 7 8 9 →